免疫脂质体作为阿苯达唑载体治疗小鼠泡球蚴病实验研究  

THE EXPERIMENTAL THERAPY AGAINST ALVEOCOCCUS IN MICE WITH IMMUNOLIPOSOMECARRIED ALBENDAZOLE

作　　者：安国顺[1] 程道新[1] 

机构地区：[1]北京医科大学寄生虫学教研室

出　　处：《寄生虫与医学昆虫学报》1997年第4期211-213,共3页Acta Parasitologica et Medica Entomologica Sinica

基　　金：国家自然科学基金

摘　　要：本文观察以抗泡球蚴抗体制备免疫脂质体作为阿苯达唑载体治疗小鼠继发性泡球蚴病的疗效。阿苯达唑免疫脂质体对小鼠泡球蚴抑制率为７９．８％，既高于单用阿苯达唑的抑制率（１５．４６％，Ｐ＜０．０１），也高于阿苯达唑脂质体的抑制率（４２．７８％，Ｐ＜０．０１）。组织学检查表明载药免疫脂质体对泡球蚴损伤程度最强，坏死及纤维化比例最高。这些结果提示免疫脂质体做载体可提高阿苯达唑对泡球蚴的治疗效果。The present study investigated the therapeutic effect carried by immunoliposome which was covalently linked with monoclonal antibody against alveococcus on mice alveococcus of albendazole (ABZ).It was found that the inhibitory rate of immunoliposomecarried ABZ on mice alveococcus was 7980% which was higher than both that of ABZ(1546%,P<001) and of ABZimmunoliposome(4278%,P<001) .Histological examination also showed that ABZimmunoliposime had the strongest damage on alveococcus and the highest ratio of necrosis and fibrosis.These results showed that using immunoliposome as a carrier can potentiate the therapeutic effect of albendazole on alveolar hydatides.

关 键 词：脂质体 阿苯达唑 泡球蚴病 

分 类 号：R532.305[医药卫生—内科学] R944.9[医药卫生—临床医学]